Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Dual-database pharmacovigilance analysis based on FAERS and JADER combined with network pharmacology to explore fulvestrant-associated respiratory toxicity.

Created on 15 Nov 2026

Authors

Wenkai Pan, Yuyan Xu, Zhenyong Shao, Xiaolin Ren, Wangjin Xu

Published in

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. Volume 34. Issue 12. Nov 14, 2026. Epub Nov 14, 2026.

Abstract

Fulvestrant serves as cornerstone endocrine therapy for hormone receptor-positive (HR-positive) advanced breast cancer. Recent reports indicate safety concerns regarding respiratory toxicity. This study systematically characterized fulvestrant-related respiratory adverse events (adverse events, AEs) using two independent spontaneous reporting databases (FAERS and JADER) for cross-verification and investigated underlying mechanisms.
Disproportionality analysis utilized two post-marketing surveillance databases, the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER), applying reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) methods for respiratory adverse event signal detection. Fulvestrant targets were predicted using SwissTargetPrediction, TargetNet, and Therapeutic Target Database (TTD). Lung disease-related genes were identified from GeneCards and Online Mendelian Inheritance in Man (OMIM). Overlapping targets underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. A protein-protein interaction (PPI) network was constructed with STRING and Cytoscape, core genes identified by maximum clique centrality (MCC) algorithm. CB-Dock2 platform performed molecular docking between fulvestrant and key targets.
A total of 6988 fulvestrant-related reports were included from FAERS with 896 respiratory toxicity cases, while 1582 fulvestrant-associated adverse event reports were retrieved from JADER, covering 154 respiratory toxicity cases. Twenty-two respiratory adverse event signals were detected in FAERS, among which nine consistent positive signals were replicated in JADER, including pleural effusion (ROR = 5.38), interstitial lung disease (ROR = 3.94), and dyspnea (ROR = 1.50). Median time to onset was 70 days (interquartile range 21-227 days). Network pharmacology analysis identified 78 overlapping targets between fulvestrant and lung diseases. Enrichment analysis indicated involvement of inflammatory response, immune regulation, oxidative stress pathways, tumor necrosis factor (TNF) signaling pathway, and interleukin 17 (IL-17) signaling pathway. Molecular docking suggested favorable predicted binding conformations between fulvestrant and several core proteins, including mitogen-activated protein kinase 14 (MAPK14), hypoxia inducible factor 1 subunit alpha (HIF1A), and mitogen-activated protein kinase 1 (MAPK1), although these findings remain computational and require further validation.
This hypothesis-generating integrated dual-database pharmacovigilance and network pharmacology analysis revealed significant association between fulvestrant and multiple respiratory toxicities, often occurring early during treatment. Potential mechanisms may involve inflammatory response, immune dysregulation, and oxidative stress-related pathways. The molecular docking findings provide exploratory computational support only and do not constitute direct evidence of in vivo interactions or causal mechanisms. Cross-database validation greatly improved the robustness of our analytical results, yet definite causality still cannot be established due to inherent limitations of spontaneous reporting systems. These findings require external validation and experimental verification and provide theoretical basis for clinical risk management and further mechanistic research.

PMID:
43033271
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement